Sana Biotechnology (SANA) FY Conference June 10, 2025 08:40 AM ET Speaker0 Great. Good morning, everyone. Thank you so much for joining us. Really pleased to have with us this morning Doctor. Steve Haar, who's the President and CEO of Sana Therapeutics. I'm Salveen Richter. I cover the biotechnology sector. Steve, before we jump into the programs here, perhaps level set us with where the company stands today regarding the portfolio strategy and key priorities and walk us through what we should look to from ...

Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetesSEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cel ...

Summary of Sana Biotechnology (SANA) Conference Call Company Overview - **Company**: Sana Biotechnology (SANA) - **Focus**: Development of innovative therapies for type one diabetes and autoimmune disorders through gene modification and hypoimmune platforms [4][5][6] Key Points and Arguments Hypoimmune Platform - **Objective**: To hide cells from immune recognition to overcome allogeneic and autoimmune rejection [5][10] - **Significant Achievement**: Successful transplantation of gene-modified beta cells into a type one diabetic patient without the need for immunosuppression, marking a potential breakthrough in treatment [6][20][66] - **Core Product**: SC451, a gene-modified stem cell-derived pancreatic islet aimed at providing a functional cure for type one diabetes with a single injection [7][66] Type One Diabetes - **Market Need**: Approximately 10 million people globally suffer from type one diabetes, with a significantly reduced life expectancy and no disruptive therapies developed in over a century [15][16] - **Current Treatments**: Traditional methods involve lifelong insulin therapy or cadaveric islet transplants, which are not scalable and require immunosuppression [17][18] - **Clinical Trial**: An investigator-sponsored trial in Sweden demonstrated that gene-modified islet cells can function without immunosuppression, with promising early results [20][22][68] Efficacy and Safety - **Key Outcomes**: The patient in the trial is producing insulin for the first time in over 30 years, with stable C-peptide levels indicating functional beta cells [23][24][66] - **Immunological Response**: The hypoimmune cells showed no T cell or antibody response, indicating successful evasion of the immune system [35][66] Future Developments - **IND Filing**: Plans to file an Investigational New Drug (IND) application next year, with ongoing work to scale production and ensure safety [38][41][65] - **Additional Programs**: Exploration of allogeneic CAR T cell therapies for autoimmune disorders, with a focus on scalability and efficacy [46][50][54] Other Important Content - **Financial Considerations**: The company acknowledges the need for additional capital to support ongoing and future studies [10][41] - **Upcoming Data Releases**: Anticipation of data presentations at the American Diabetes Association meeting, with a focus on the six-month results from the clinical trial [22][68] - **Comparative Analysis**: The company positions its hypoimmune platform as a significant advancement over existing therapies, likening it to the evolution from electric cars needing to be plugged in to those with functional batteries [66][67] This summary encapsulates the critical insights and developments discussed during the conference call, highlighting Sana Biotechnology's innovative approaches and the potential impact on treating type one diabetes and autoimmune disorders.

SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8: ...

Core Insights - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Offerings - Biotech Analysis Central offers a library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and live chat features for investors [2]. - The service is priced at $49 per month, with a discounted annual plan available for $399, representing a 33.50% savings [1]. Group 2: Analyst Background - The author of the article runs the Biotech Analysis Central service and emphasizes the importance of deep analysis for informed investment decisions in the healthcare sector [2]. - The article does not indicate any personal investment positions in the companies discussed, ensuring an unbiased perspective [3].

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sana Biotechnology, Inc. ("Sana Biotechnology, Inc." or the "Company") (NASDAQ: SANA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sana Biotechnology, Inc. investors who were adversely affected by alleged securities fraud between March 17, 2023 and November 4, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO N ...

NEW YORK, May 19, 2025 /PRNewswire/ --The Gross Law Firm issues the following notice to shareholders of Sana Biotechnology, Inc. (NASDAQ: SANA).Shareholders who purchased shares of SANA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/sana-biotechnology-inc-loss-submission-form/?id=148815&from=4CLASS PERIOD: March 1 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Sana securities between March 17, 2023, and November 4, 2024, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Sana made false or misleading statements regarding its financial stability and the potential of its product candidates, including SC291, SC379, and SG299 [4]. - It is claimed that Sana was at significant risk of insufficient funds to maintain operations and that the company was likely to reduce funding for certain product candidates and significantly cut its workforce [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations and Financial Concerns - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2]. - To preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [2]. - The defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the relevant timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].